Company news
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) news
Paradigm Biopharmaceuticals Ltd. news releases on 6ix. Latest, May 28, 2019: PAR reports consistent pain reduction in knee OA of patients
Press releases — page 4
PAR reports consistent pain reduction in knee OA of patients
May 27, 2019
PAR CORRECTS AFR ARTICLE
May 21, 2019
Successful Completion of Retail Entitlement Offer
May 8, 2019
Paradigm Corporate Update - May 2019
May 7, 2019
Quarterly Report and Appendix 4C - quarterly
April 30, 2019
Completion of Institutional Entitlement Offer
April 23, 2019
PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
April 16, 2019
PARADIGM UPDATED CORPORATE PRESENTATION
April 14, 2019
Paradigm (PAR) Updated Investor Presentation
March 12, 2019
S&P DJI Announces March 2019 Quarterly Rebalance
March 7, 2019
PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES
February 13, 2019
PARADIGMS SUPPLEMENTARY PHASE 2B DATA
December 19, 2018
PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS
December 17, 2018
PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION
December 6, 2018
Paradigms AGM Presentation
November 26, 2018
Paradigm in-licenses treatment for rare joint disease
November 21, 2018
PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND
November 14, 2018
PAR reports pain reduction in 145 people with osteoarthritis
November 7, 2018
Paradigm Agreement With USA Past Players Network
October 24, 2018
PAR REPORTS PAIN REDUCTION IN OA PATIENTS
September 24, 2018
Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
August 28, 2018
Appendix 4E and 2018 Annual Report
August 24, 2018
PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN
August 14, 2018
PAR achieves 100 per cent recruitment in Phase 2b OA Trial
August 5, 2018
PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINED
June 14, 2018
Paradigm OA Phase 2b Clinical Trial over 80% Recruited
May 16, 2018
PARADIGMs PHASE 2 CLINICAL DATA UPDATE
March 26, 2018
PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50%
February 28, 2018
Half Year Accounts
February 22, 2018
Quarterly Update and Appendix 4C
January 29, 2018
PARs European Patent Granted for Bone Marrow Edema Lesions
January 15, 2018
Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
November 22, 2017
Paradigms ACL Phase 2 Clinical Trial Success
November 13, 2017
PAR Successfully Completes A$5.75m Placement
November 5, 2017
First Participant Dosed in PARs Phase 2b OA Clinical Trial
October 29, 2017
PAR REPORTS PAIN REDUCTION IN 83% OF OSTEOARTHRITIS PATIENTS
October 9, 2017
PARs Osteoarthritis Phase 2 Receives Ethics Approval
September 18, 2017
Paradigm Phase 2 Ross River Virus Clinical Trial Update
September 13, 2017
A PARADIGM SHIFT IN TREATING OSTEOARTHRITIS PAIN
September 10, 2017
Appendix 4E and 2017 Annual Report
August 29, 2017
Paradigm (PAR) - First Ross River Trial Participant Treated
August 8, 2017
Paradigm To Commence Phase 2 Ross River Virus Clinical Trial
July 9, 2017
Paradigm Enters Heart Failure Market
June 19, 2017
Hay Fever Trial Update
June 15, 2017
Paradigm Receives Ethics Approval for Ross River Trial
May 21, 2017
Paradigms preclinical hay fever trial published
May 15, 2017
Paradigm Government grant for Ross River virus research
May 10, 2017
Paradigm March Quarter Update & Appendix 4C
April 27, 2017
Final participant treated in Phase 2 hay fever trial
March 22, 2017
Paradigm receives $1.34 million R&D tax incentive rebate
March 21, 2017